Case number 2020-1871
Sanofi-Aventis Deutschland v. Mylan Pharmaceuticals Inc. > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Feb 22, 2022 | 121 | Mandate issued to the United States Patent and Trademark Office. Service as of this date by the Clerk of Court. [832654] [20-1871, 20-2029, 20-2032, 20-2033, 20-2034, 20-2159] [MVH] [Entered: 02/22/2022 02:07 PM] (3) |
| Jan 2, 2022 | 0 | SANOFI-AVENTIS DEUTSCHLAND v. MYLAN PHARMACEUTICALS INC. [OPINION] [nonprecedential] (0) |
| Dec 29, 2021 | 119 | OPINION filed for the court by Dyk, Circuit Judge; Clevenger, Circuit Judge and Taranto, Circuit Judge. Nonprecedential Per Curiam Opinion. Service as of this date by the Clerk of Court. [821652] [20-1871, 20-2029, 20-2032, 20-2033, 20-2034, 20-2159] [MVH] [Entered: 12/29/2021 09:49 AM] (6) |
| Dec 29, 2021 | 120 | JUDGMENT. AFFIRMED IN PART, DISMISSED IN PART. Terminated on the merits after oral argument. COSTS: Costs taxed against Appellant(s). Mandate to issue in due course. For information regarding costs, petitions for rehearing, and petitions for writs of certiorari click here. Service as of this date by the Clerk of Court. [821654] [20-1871, 20-2029, 20-2032, 20-2033, 20-2034, 20-2159] [MVH] [Entered: 12/29/2021 09:50 AM] (3) |
| Dec 6, 2021 | 118 | Submitted after ORAL ARGUMENT to Panel: Dyk, Circuit Judge; Clevenger, Circuit Judge and Taranto, Circuit Judge.Arguing counsel: William Sutton Ansley for Sanofi-Aventis Deutschland GmbH and Douglas H. Carsten for Mylan Pharmaceuticals Inc.Oral Argument Audio available here. [816407] [JCP] [Entered: 12/06/2021 01:07 PM] (0) |
| Nov 8, 2021 | 115 | NOTICE OF NON-COMPLIANCE: The submission of Sanofi-Aventis Deutschland GmbH, Response to Notice of Oral Argument [114], is not in compliance with the rules of this court (see attached). Compliant document due 11/16/2021. Service as of this date by the Clerk of Court. [810840] [MJL] [Entered: 11/08/2021 01:14 PM] (1) |
| Nov 8, 2021 | 116 | Response to notice of oral argument from Intervenor Andrew Hirshfeld. Service: 11/08/2021 by email. [810892] [20-1871] [Kakoli Caprihan] [Entered: 11/08/2021 02:39 PM] (1) |
| Nov 8, 2021 | 117 | Corrected Response to notice of oral argument from Appellant Sanofi-Aventis Deutschland GmbH. Service: 11/08/2021 by email. [810914] [20-1871] [William Ansley] [Entered: 11/08/2021 03:04 PM] (3) |
| Nov 2, 2021 | 114 | Response to notice of oral argument from Appellant Sanofi-Aventis Deutschland GmbH. Service: 11/02/2021 by email. [809735] [20-1871]. This document is non-compliant. See Doc. No. [115]. [Adam Banks] [Entered: 11/02/2021 02:29 PM] (3) |
| Oct 25, 2021 | 112 | NOTICE OF NON-COMPLIANCE: The submission of Mylan Pharmaceuticals Inc., Response to Notice of Oral Argument [111], is not in compliance with the rules of this court (see attached). Compliant document due 11/01/2021. Service as of this date by the Clerk of Court. [807833] [MJL] [Entered: 10/25/2021 08:30 AM] (1) |
| Oct 25, 2021 | 113 | Corrected Response to notice of oral argument from Appellee Mylan Pharmaceuticals Inc.. Service: 10/25/2021 by email. [807923] [20-1871] [Douglas Carsten] [Entered: 10/25/2021 11:04 AM] (3) |
| Oct 22, 2021 | 111 | Response to notice of oral argument from Appellee Mylan Pharmaceuticals Inc.. Service: 10/22/2021 by email. [807701] [20-1871]. This document is non-compliant. See Doc. No. [112]. [Douglas Carsten] [Entered: 10/22/2021 02:07 PM] (3) |
| Oct 21, 2021 | 110 | NOTICE OF ORAL ARGUMENT. Panel: 2112B. Case scheduled December 6, 2021. Response to Notice of Oral Argument due: 11/15/2021. Please review the attached Notice. The response to notice of oral argument form can be found here. The Oral Argument Guide can be found here. Service as of this date by the Clerk of Court. [807402] [JCP] [Entered: 10/21/2021 04:45 PM] (2) |
| Sep 9, 2021 | 108 | ORDER filed granting motion to reschedule argument filed by Appellant Sanofi-Aventis Deutschland GmbH in 20-1871 [104], in 20-2066 [795903-2], in 20-2071 [795905-2] and in 21-1262 [795906-2]. By: Merits Panel (Per Curiam). Service as of this date by the Clerk of Court. [798113] [20-1871, 20-2066, 20-2071, 21-1262] [MVH] [Entered: 09/09/2021 04:05 PM] (5) |
| Sep 9, 2021 | 109 | The following conflict dates submitted by Sanofi-Aventis Deutschland GmbH have been accepted by the court: 11/01/2021, 11/02/2021, 11/03/2021, 11/04/2021, 11/05/2021. [798122] [MVH] [Entered: 09/09/2021 04:14 PM] (0) |
| Sep 3, 2021 | 107 | REPLY of Appellant Sanofi-Aventis Deutschland GmbH to response [105]. Service: 09/03/2021 by email. [797126] [20-1871] [Adam Banks] [Entered: 09/03/2021 12:03 PM] (8) |
| Sep 2, 2021 | 105 | RESPONSE of Appellee Mylan Pharmaceuticals Inc. to Doc No. [104]. Service: 09/02/2021 by email. [797033] [20-1871] [Elham Steiner] [Entered: 09/02/2021 06:41 PM] (6) |
| Sep 2, 2021 | 106 | Response to notice of oral argument from Appellee Mylan Pharmaceuticals Inc.. Service: 09/02/2021 by email. [797037] [20-1871] [Douglas Carsten] [Entered: 09/02/2021 06:50 PM] (3) |
| Aug 30, 2021 | 104 | MOTION of Appellant Sanofi-Aventis Deutschland GmbH to reschedule argument. Service: 08/30/2021 by email. [795901] [20-1871] [Adam Banks] [Entered: 08/30/2021 10:56 AM] (10) |
| Aug 20, 2021 | 103 | NOTICE OF ORAL ARGUMENT. Panel: 2110H. Case scheduled October 6, 2021. Response to Notice of Oral Argument due: 09/15/2021. Please review the attached Notice. The response to notice of oral argument form can be found here. The Oral Argument Guide can be found here. Service as of this date by the Clerk of Court. [794474] [MJL] [Entered: 08/20/2021 04:55 PM] (2) |
| Aug 9, 2021 | 102 | Notice from Intervenor Andrew Hirshfeld regarding conflicts with oral argument. None. Service: 08/09/2021 by email. [791342] [20-1871] [Kakoli Caprihan] [Entered: 08/09/2021 10:46 AM] (0) |
| Aug 6, 2021 | 101 | Notice from Appellant Sanofi-Aventis Deutschland GmbH regarding conflicts with oral argument. Service: 08/06/2021 by email. [791027] [20-1871] [Adam Banks] [Entered: 08/06/2021 10:09 AM] (1) |
| Aug 3, 2021 | 100 | Notice from Appellee Mylan Pharmaceuticals Inc. regarding conflicts with oral argument. None. Service: 08/03/2021 by email. [790322] [20-1871] [Richard Torczon] [Entered: 08/03/2021 01:42 PM] (0) |
| Aug 2, 2021 | 99 | Notice to Advise of Scheduling Conflicts. Arguing counsel must advise of, and show good cause for, any scheduling conflicts during the upcoming court session months listed in the attached notice. The Response to Notice to Advise of Scheduling Conflicts can be found here. The Oral Argument Guide can be found here. [789818] [EKD] [Entered: 08/02/2021 10:14 AM] (1) |
| Jul 29, 2021 | 98 | ORDER filed lifting stay. These appeals will be scheduled for oral argument in due course. The Clerk of Court shall transmit this order to the merits panel assigned to these appeals. (Per Curiam). Service as of this date by the Clerk of Court. [789349] [LMS] [Entered: 07/29/2021 11:16 AM] (3) |
| Jul 19, 2021 | 96 | RESPONSE of Appellee Mylan Pharmaceuticals Inc. to Doc No. [93], [93], [93]. Service: 07/19/2021 by email. [786988] [20-1871] [Richard Torczon] [Entered: 07/19/2021 11:06 AM] (10) |
| Jul 19, 2021 | 97 | RESPONSE of Appellee Mylan Pharmaceuticals Inc. to Doc No. [93], [93], [93]. Service: 07/19/2021 by email. [786996] [20-1871] [Richard Torczon] [Entered: 07/19/2021 11:26 AM] (10) |
| Jul 16, 2021 | 95 | RESPONSE of Intervenor Andrew Hirshfeld to Doc. No. [93], [93], [93]. Service: 07/16/2021 by email. [786753] [20-1871] [Kakoli Caprihan] [Entered: 07/16/2021 12:23 PM] (5) |
| Jul 7, 2021 | 94 | RESPONSE of Appellant Sanofi-Aventis Deutschland GmbH to Doc No. [93], [93], [93]. Service: 07/07/2021 by email. [784659] [20-1871] [Adam Banks] [Entered: 07/07/2021 05:45 PM] (8) |
| Jun 23, 2021 | 93 | ORDER filed. Within 14 days from the date of this order, the parties that raised an Appointments Clause challenge shall file a brief, not to exceed 10 pages double-spaced, explaining how they believe their cases should proceed in light of Arthrex. Responses from the other parties, including the United States Patent and Trademark Office, subject to the same length restrictions, are due within 14 days thereafter. All deadlines and proceedings are stayed. Service as of this date by the Clerk of Court. [782106] [20-1587, 20-1588, 20-1589, 20-1590, 20-1591, 20-1592, 20-1593, 20-1594, 20-1654, 20-1747, 20-1748, 20-1749, 20-1750, 20-1751, 20-1752, 20-1871, 20-2029, 20-2032, 20-2033, 20-2034, 20-2159] [MJL] [Entered: 06/23/2021 04:58 PM] (2) |
| Jun 14, 2021 | 92 | The following conflict dates submitted by Adam Banks for Sanofi-Aventis Deutschland GmbH have been accepted by the court: 08/02/2021, 08/03/2021, 08/04/2021, 08/05/2021, 08/06/2021, 08/30/2021, 08/31/2021, 09/01/2021, 09/02/2021, 09/03/2021. [779984] [MVH] [Entered: 06/14/2021 09:40 AM] (0) |
| Jun 7, 2021 | 91 | Corrected Entry of appearance for Douglas H. Carsten; Adam Burrowbridge as counsel for Appellee Mylan Pharmaceuticals Inc.. Service: 06/07/2021 by email. [778694] [20-1871] [Richard Torczon] [Entered: 06/07/2021 10:05 AM] (2) |
| Jun 3, 2021 | 89 | Supplementary Media Appendix received on USB from Sanofi-Aventis Deutschland GmbH. Number of copies: 4. [778268] [VDW] [Entered: 06/03/2021 10:02 AM] (0) |
| Jun 3, 2021 | 90 | 6 paper copies of Doc. No. [67] received from Appellee Mylan Pharmaceuticals Inc.. [778551] [VDW] [Entered: 06/04/2021 01:22 PM] (0) |
| Jun 2, 2021 | 88 | NOTICE OF NON-COMPLIANCE: The submissions of Appellee Mylan Pharmaceuticals Inc. in 20-1871, 20-2066, and 20-2071, and Appellees Biocon Ltd., Biocon Research Ltd., Biocon S.A., Biocon Sdn.Bhd, and Mylan GmbH in 21-1262, Entries of Appearance [83], [777227-2], [777229-2], [777233-2], are not in compliance with the rules of this court (see attached). Compliant documents are due on 06/09/2021. Service as of this date by the Clerk of Court. [778143] [20-1871, 20-2066, 20-2071, 21-1262] [EKD] [Entered: 06/02/2021 02:35 PM] (1) |
| Jun 1, 2021 | 87 | Notice from Appellant Sanofi-Aventis Deutschland GmbH regarding conflicts with oral argument. Service: 06/01/2021 by email. [777936] [20-1871] [Adam Banks] [Entered: 06/01/2021 05:04 PM] (5) |
| May 28, 2021 | 85 | 6 paper copies of Doc. No. [62] received from Intervenor Andrew Hirshfeld. [777513] [VDW] [Entered: 05/28/2021 09:11 AM] (0) |
| May 27, 2021 | 84 | Notice from Appellee Mylan Pharmaceuticals Inc. regarding conflicts with oral argument. Service: 05/27/2021 by email. [777412] [20-1871] [Richard Torczon] [Entered: 05/27/2021 01:59 PM] (4) |
| May 26, 2021 | 83 | Entry of appearance for Douglas H. Carsten; Adam Burrowbridge as counsel for Appellee Mylan Pharmaceuticals Inc.. Service: 05/26/2021 by email. [777225] [20-1871] This document is non-compliant. See Doc No. [88] [Richard Torczon] [Entered: 05/26/2021 01:07 PM] (2) |
| May 26, 2021 | 86 | 6 paper copies of Doc. No. [78], [77], [65] received from Appellant Sanofi-Aventis Deutschland GmbH. [777606] [VDW] [Entered: 05/28/2021 01:51 PM] (0) |
| May 25, 2021 | 81 | Notice to counsel: The Clerk's Office directs that outstanding paper copies of all briefs and appendices in this case must be submitted on or before June 2, 2021. See Administrative Order No. 20-01 (Mar. 20, 2020). [777003] [EKD] [Entered: 05/25/2021 02:40 PM] (0) |
| May 25, 2021 | 82 | Notice to Advise of Scheduling Conflicts. Arguing counsel must advise of, and show good cause for, any scheduling conflicts during the upcoming court session months listed in the attached notice. The Response to Notice to Advise of Scheduling Conflicts can be found here. The Oral Argument Guide can be found here. [777004] [EKD] [Entered: 05/25/2021 02:40 PM] (1) |
| Apr 19, 2021 | 78 | MODIFIED ENTRY: APPENDIX FILED by Appellant Sanofi-Aventis Deutschland GmbH. Service: 04/19/2021 by email. [769751] --[Edited 04/20/2021 by EKD - compliance review complete] [Adam Banks] [Entered: 04/19/2021 08:58 PM] (1146) |
| Apr 19, 2021 | 79 | Certificate of Compliance with Fed. Cir. R. 25.1(c)(2) for Appellant Sanofi-Aventis Deutschland GmbH. Service: 04/19/2021 by email. [769755] [20-1871] [Adam Banks] [Entered: 04/19/2021 09:05 PM] (6) |
| Apr 19, 2021 | 80 | Joint Statement of Compliance with Fed. Cir. R. 33 for Appellant Sanofi-Aventis Deutschland GmbH. Service: 04/19/2021 by email. [769771] [20-1871] [Adam Banks] [Entered: 04/19/2021 11:00 PM] (6) |
| Apr 12, 2021 | 76 | Amended Certificate of Interest for Appellant Sanofi-Aventis Deutschland GmbH. Service: 04/12/2021 by email. [768145] [20-1871] [Adam Banks] [Entered: 04/12/2021 09:49 PM] (3) |
| Apr 12, 2021 | 77 | MODIFIED ENTRY: REPLY BRIEF FILED by Appellant Sanofi-Aventis Deutschland GmbH. Service: 04/12/2021 by email. Unless ordered otherwise, any responsive deadline runs from the date of service of this brief. See Fed. Cir. R. 31. [768146] --[Edited 04/13/2021 by EKD - compliance review complete] [Adam Banks] [Entered: 04/12/2021 09:51 PM] (38) |
| Mar 29, 2021 | 75 | **TEXT ONLY** ORDER granting motion to withdraw attorney Douglas H. Carsten [71] filed by Appellee Mylan Pharmaceuticals Inc. Service as of this date by the Clerk of Court. This order has been issued without an attached document and is official and binding. [765276] [EKD] [Entered: 03/29/2021 09:01 AM] (0) |
| Mar 26, 2021 | 74 | Corrected Entry of appearance for Richard Torczon; Steffen N. Johnson as counsel for Appellee Mylan Pharmaceuticals Inc.. Service: 03/26/2021 by email. [765043] [20-1871] [Richard Torczon] [Entered: 03/26/2021 01:36 PM] (0) |
| Mar 25, 2021 | 73 | NOTICE OF NON-COMPLIANCE: The submission of Appellee Mylan Pharmaceuticals Inc., Entry of Appearance [72], is not in compliance with the rules of this court (see attached). Compliant document is due on 04/01/2021. Service as of this date by the Clerk of Court. [764799] [EKD] [Entered: 03/25/2021 04:09 PM] (0) |
| Mar 24, 2021 | 70 | Amended Certificate of Interest for Appellee Mylan Pharmaceuticals Inc.. Service: 03/24/2021 by email. [764504] [20-1871] [Richard Torczon] [Entered: 03/24/2021 02:06 PM] (0) |
| Mar 24, 2021 | 71 | MOTION of Appellee Mylan Pharmaceuticals Inc. to withdraw counsel Douglas H. Carsten. Service: 03/24/2021 by email. [764510] [20-1871] [Richard Torczon] [Entered: 03/24/2021 02:17 PM] (0) |
| Mar 24, 2021 | 72 | Entry of appearance for Richard Torczon; Steffen N. Johnson as counsel for Appellee Mylan Pharmaceuticals Inc. Service: 03/24/2021 by email. [764514] [20-1871] This document is non-compliant. See Doc No. [73] [Richard Torczon] [Entered: 03/24/2021 02:21 PM] (0) |
| Mar 12, 2021 | 69 | **TEXT ONLY** ORDER granting motion to extend time to file brief [68] filed by Appellant Sanofi-Aventis Deutschland GmbH. The reply brief is due 04/12/2021. Service as of this date by the Clerk of Court. This order has been issued without an attached document and is official and binding. [761782] [EKD] [Entered: 03/12/2021 08:57 AM] (0) |
| Mar 11, 2021 | 68 | MOTION of Appellant Sanofi-Aventis Deutschland GmbH to extend the time to 04/12/2021 to file brief. Service: 03/11/2021 by email. [761741] [20-1871] [Adam Banks] [Entered: 03/11/2021 08:07 PM] (0) |
| Mar 5, 2021 | 66 | Notice of Correction to Doc No. [65] for Appellant Sanofi-Aventis Deutschland GmbH. Service: 03/05/2021 by email. [760545] [20-1871] [Adam Banks] [Entered: 03/05/2021 05:52 PM] (0) |
| Mar 5, 2021 | 67 | MODIFIED ENTRY: CORRECTED RESPONSE BRIEF FILED by Appellee Mylan Pharmaceuticals Inc. Service: 03/05/2021 by email. [760568] --[Edited 03/08/2021 by EKD - compliance review complete] [Richard Torczon] [Entered: 03/05/2021 08:30 PM] (0) |
| Mar 5, 2021 | 64 | Amended Certificate of Interest for Appellant Sanofi-Aventis Deutschland GmbH. Service: 03/05/2021 by email. [760543] [20-1871] [Adam Banks] [Entered: 03/05/2021 05:46 PM] (3) |
| Mar 5, 2021 | 65 | MODIFIED ENTRY: CORRECTED OPENING BRIEF FILED by Appellant Sanofi-Aventis Deutschland GmbH. Service: 03/05/2021 by email. [760544] --[Edited 03/08/2021 by EKD - compliance review complete] [Adam Banks] [Entered: 03/05/2021 05:49 PM] (655) |
| Mar 4, 2021 | 62 | MODIFIED ENTRY: CORRECTED INTERVENOR BRIEF FILED by Intervenor Andrew Hirshfeld. Service: 03/04/2021 by email. [760019] --[Edited 03/05/2021 by EKD - compliance review complete] [Kakoli Caprihan] [Entered: 03/04/2021 11:59 AM] (16) |
| Mar 4, 2021 | 63 | Amended Certificate of Interest for Appellee Mylan Pharmaceuticals Inc. Service: 03/04/2021 by email. [760207] [20-1871]--[Edited 03/08/2021 by JAL to add party filer] [Richard Torczon] [Entered: 03/04/2021 06:35 PM] (3) |
| Mar 3, 2021 | 61 | NOTICE OF NON-COMPLIANCE: The submissions of Appellant Sanofi-Aventis Deutschland GmbH, Corrected Opening Brief [57], Appellee Mylan Pharmaceuticals Inc., Response Brief [60], and Intervenor Andrew Hirshfeld, Intervenor Brief [59], are not in compliance with the rules of this court (see attached). Compliant documents are due on 03/10/2021. Unless ordered otherwise, the deadline for any responsive filing runs from service of the original version. Service as of this date by the Clerk of Court. [759753] [EKD] [Entered: 03/03/2021 11:32 AM] (2) |
| Mar 2, 2021 | 58 | Entry of appearance for Brian Racilla; Daniel Kazhdan as counsel for Intervenor Andrew Hirshfeld. Service: 03/02/2021 by email. [759502] [20-1871] [Brian Racilla] [Entered: 03/02/2021 01:41 PM] (2) |
| Mar 2, 2021 | 59 | INTERVENOR BRIEF FILED by Intervenor Andrew Hirshfeld. Service: 03/02/2021 by email. [759523] [20-1871] This document is non-compliant. See Doc No. [61] [Kakoli Caprihan] [Entered: 03/02/2021 02:10 PM] (15) |
| Mar 2, 2021 | 60 | RESPONSE BRIEF FILED by Appellee Mylan Pharmaceuticals Inc.. Service: 03/02/2021 by email. [759683] [20-1871] This document is non-compliant. See Doc No. [61] [Richard Torczon] [Entered: 03/02/2021 09:27 PM] (76) |
| Feb 26, 2021 | 57 | CORRECTED OPENING BRIEF FILED by Appellant Sanofi-Aventis Deutschland GmbH. Service: 02/26/2021 by email. [758857] [20-1871] This document is non-compliant. See Doc No. [61] [Adam Banks] [Entered: 02/26/2021 10:11 AM] (654) |
| Feb 25, 2021 | 56 | NOTICE OF NON-COMPLIANCE: The submission of Appellant Sanofi-Aventis Deutschland GmbH, Opening Brief [43], is not in compliance with the rules of this court (see attached). Compliant document is due on 03/04/2021. Service as of this date by the Clerk of Court. [758593] [EKD] [Entered: 02/25/2021 11:23 AM] (1) |
| Feb 4, 2021 | 55 | Docketing Statement for the Intervenor Andrew Hirshfeld. Service: 02/04/2021 by email. [753950] [20-1871] [Kakoli Caprihan] [Entered: 02/04/2021 11:02 AM] (2) |
| Jan 27, 2021 | 53 | ORDER granting [50] [748891-2] [748893-2] the motions. The revised official captions are reflected above. Appeal No. 2020-2144 is withdrawn. Each side shall bear its own costs with respect to Appeal No. 2020-2144. ISSUED AS A MANDATE (as to Appeal No. 2020-2144 only): January 27, 2021. Service as of this date by the Clerk of Court. [751964] [20-1871, 20-2029, 20-2032, 20-2033, 20-2034, 20-2159, 20-2066, 20-2068, 20-2069, 20-2071, 20-2144] [LMS] [Entered: 01/27/2021 08:28 AM] (5) |
| Jan 27, 2021 | 54 | Note to File: The following cases shall be considered companion cases and assigned to the same merits panel: 20-1871 and 21-1262. [751977] [EKD] [Entered: 01/27/2021 09:10 AM] (0) |
| Jan 22, 2021 | 52 | Official caption revised to reflect Andrew Hirshfeld, Performing the Functions and Duties of the Under Secretary of Commerce for Intellectual Property and Director of the United States Patent and Trademark Office, as Intervenor (see attached). Service as of this date by the Clerk of Court. [751244] [EKD] [Entered: 01/22/2021 04:27 PM] (3) |
| Jan 21, 2021 | 51 | ORDER granting motions [40], [737385-2], [737387-2], & [737390-2] to the extent that the appeals shall be considered companion cases and assigned to the same merits panel. Sanofi’s motion to dismiss [727706-2] is denied. The parties are directed to address the standing issues in their briefs. Pfizer’s motion [731906-2] is granted to the extent provided herein. ECF Nos. 14 and 15 in Appeal Nos. 2020-2071, -2139, -2144 are accepted for filing. The Director of the United States Patent and Trademark Office is added as an intervenor. The revised official captions are reflected in the order. (See order for briefing details) Service as of this date by the Clerk of Court. [750712] [20-1871, 20-2029, 20-2159, 20-2066, 20-2071, 21-1262] [NL] [Entered: 01/21/2021 04:36 PM] (6) |
| Jan 12, 2021 | 50 | MOTION of Appellee Pfizer Inc. to withdraw party, Pfizer Inc., as a party to this appeal. Service: 01/12/2021 by email. [748890] [20-1871] [Thomas Meloro] [Entered: 01/12/2021 05:14 PM] (7) |
| Jan 6, 2021 | 48 | Notice of Intervention pursuant to the provisions of 35 USC Section 143 from the Director of the United States Patent and Trademark Office. Service: 01/06/2021 by email. [747339] [20-1871] [Kakoli Caprihan] [Entered: 01/06/2021 12:38 PM] (2) |
| Jan 6, 2021 | 49 | Entry of appearance for Kakoli Caprihan; Thomas W. Krause; Farheena Y. Rasheed as counsel for Intervenor - Director U.S. Patent and Trademark Office. Service: 01/06/2021 by email. [747343] [20-1871] [Kakoli Caprihan] [Entered: 01/06/2021 12:40 PM] (2) |
| Dec 22, 2020 | 47 | Entry of appearance for Thomas J. Meloro; Charles B. Klein; Jovial Wong; Dan H. Hoang; Michael W. Johnson; Devon W. Edwards as counsel for Appellee Pfizer Inc.. Service: 12/22/2020 by email. [744778] [20-1871] [Thomas Meloro] [Entered: 12/22/2020 02:26 PM] (2) |
| Dec 7, 2020 | 46 | ORDER Notice of Sanofi's constitutional challenges [44] [739052-2] [739053-2] are hereby certified to the Attorney General. No later than 30 days from the date of filing of this order, the Attorney General is directed to inform this court whether the United States intends to intervene in these appeals. The briefing schedules are stayed. Service as of this date by the Clerk of Court. [740564] [20-1871, 20-2066, 20-2071] [LMS] [Entered: 12/07/2020 09:36 AM] (4) |
| Dec 2, 2020 | 45 | REPLY of Appellant Sanofi-Aventis Deutschland GmbH to response [41]. Service: 12/02/2020 by email. [739748] [20-1871] [Adam Banks] [Entered: 12/02/2020 04:24 PM] (9) |
| Nov 30, 2020 | 42 | Certificate of Interest for Appellant Sanofi-Aventis Deutschland GmbH. Service: 11/30/2020 by email. [738979] [20-1871] [Anish Desai] [Entered: 11/30/2020 08:18 PM] (3) |
| Nov 30, 2020 | 43 | OPENING BRIEF FILED by Appellant Sanofi-Aventis Deutschland GmbH. Service: 11/30/2020 by email. [739049] [20-1871] This document is non-compliant. See Doc No. [56] [Adam Banks] [Entered: 11/30/2020 11:21 PM] (654) |
| Nov 30, 2020 | 44 | Notice from Appellant Sanofi-Aventis Deutschland GmbH Constitutional Question. Service: 11/30/2020 by email. [739051] [20-1871] [Adam Banks] [Entered: 11/30/2020 11:40 PM] (6) |
| Nov 25, 2020 | 41 | RESPONSE of Appellee Mylan Pharmaceuticals Inc. to the motion for other relief [40]. Service: 11/25/2020 by email. [738519] [20-1871] [Richard Torczon] [Entered: 11/25/2020 05:32 PM] (13) |
| Nov 20, 2020 | 40 | MOTION of Appellant Sanofi-Aventis Deutschland GmbH DESIGNATE APPEALS AS COMPANION CASES AND TO SET COORDINATED BRIEFING SCHEDULE. Service: 11/20/2020 by email. [737383] [20-1871] [Adam Banks] [Entered: 11/20/2020 03:30 PM] (8) |
| Sep 25, 2020 | 37 | ORDER granting motions to consolidate appeals [34], [23],[716203-2], filed by Appellant Sanofi-Aventis Deutschland GmbH. in 20-1871 and 20-2159; denying [23], [712838-3] motions to waive requirements of brief or appendix filed by Sanofi-Aventis Deutschland GmbH in 20-1871 and 20-2033; denying [23], [712838-4], motions to set briefing schedule filed by Sanofi-Aventis Deutschland GmbH in 20-1871 and 20-2033; deconsolidating appeals in 20-1871, 20-2033, and 20-2034. The stays of the briefing schedules are lifted. The opening briefs for each group of appeals are due within 60 days from the filing date of the last-filed Certified List within each group. Service as of this date by the Clerk of Court. [724420] [20-1871, 20-2029, 20-2032, 20-2033, 20-2034, 20-2159] [LMN] [Entered: 09/25/2020 10:06 AM] (4) |
| Sep 25, 2020 | 38 | Note to File: The following cases are consolidated: 20-1871 Lead with 20-2029, 20-2032, 20-2033, 20-2034, and 20-2159 Member Cases. The parties must file all documents in the lead appeal only. [724429] [20-1871, 20-2029, 20-2032, 20-2033, 20-2034, 20-2159] [LMN] [Entered: 09/25/2020 10:22 AM] (0) |
| Sep 25, 2020 | 39 | Note to File: The following cases shall be considered companion cases and assigned to the same merits panel: 20-1871, 20-2066, and 20-2071. [724604] [20-1871, 20-2066, 20-2071] [LMN] [Entered: 09/25/2020 04:36 PM] (0) |
| Sep 10, 2020 | 36 | Certified list for 20-2029, 20-2032, 20-2071, 20-2139, and 20-2144 received. Service: 09/08/2020 by email. [720624] [20-1871, 20-2029, 20-2032, 20-2071, 20-2139, 20-2144] [EKD] [Entered: 09/10/2020 09:15 AM] (279) |
| Aug 25, 2020 | 35 | ORDER staying the briefing schedules pending disposition of the motions. Service as of this date by the Clerk of Court. [717299] [20-1871, 20-2033, 20-2068, 20-2159] [LMS] [Entered: 08/25/2020 11:05 AM] (4) |
| Aug 20, 2020 | 34 | MOTION of Appellant Sanofi-Aventis Deutschland GmbH to consolidate appeals (2020-2159 and 2020-1871) [Consent: unopposed]. Service: 08/20/2020 by email. [716201] [20-1871] [Adam Banks] [Entered: 08/20/2020 02:07 PM] (8) |
| Aug 17, 2020 | 31 | Amended Entry of appearance for Charles B. Klein; Jovial Wong; Dan Hoang as counsel for Cross-Appellant Pfizer Inc.. Service: 08/17/2020 by email. [715377] [20-1871] [Charles Klein] [Entered: 08/17/2020 05:00 PM] (2) |
| Aug 17, 2020 | 32 | Amended Certificate of Interest for Cross-Appellant Pfizer Inc.. Service: 08/17/2020 by email. [715384] [20-1871] [Charles Klein] [Entered: 08/17/2020 05:07 PM] (3) |
| Aug 17, 2020 | 33 | Amended Docketing Statement for the Cross-Appellant Pfizer Inc.. Service: 08/17/2020 by email. [715386] [20-1871] [Charles Klein] [Entered: 08/17/2020 05:09 PM] (3) |
| Aug 14, 2020 | 30 | Note to File: The following cases are consolidated: 20-1871 Lead with 20-2139 and 20-2144 Cross-Appeals. The parties must file all documents in the lead appeal only. [714910] [20-1871, 20-2139, 20-2144] [EKD] [Entered: 08/14/2020 12:17 PM] (0) |
| Aug 12, 2020 | 29 | REPLY of Appellant Sanofi-Aventis Deutschland GmbH to response [28]. Service: 08/12/2020 by email. [714344] [20-1871] [Adam Banks] [Entered: 08/12/2020 09:14 AM] (14) |
| Aug 7, 2020 | 27 | Amended Certificate of Interest for Appellee Mylan Pharmaceuticals Inc.. Service: 08/07/2020 by email. [713504] [20-1871] [Douglas Carsten] [Entered: 08/07/2020 06:36 PM] (3) |
| Aug 7, 2020 | 28 | RESPONSE of Appellee Mylan Pharmaceuticals Inc. to the motion [23] filed by Appellant Sanofi-Aventis Deutschland GmbH, motion [23] filed by Appellant Sanofi-Aventis Deutschland GmbH, motion [23] filed by Appellant Sanofi-Aventis Deutschland GmbH. Service: 08/07/2020 by email. [713507] [20-1871] [Douglas Carsten] [Entered: 08/07/2020 06:44 PM] (15) |
| Aug 6, 2020 | 24 | Entry of appearance for Charles B. Klein; Jovial Wong; Dan Hoang as counsel for Appellee Pfizer Inc.. Service: 08/06/2020 by email. [713171] [20-1871] [Charles Klein] [Entered: 08/06/2020 05:52 PM] (2) |
| Aug 6, 2020 | 25 | Certificate of Interest for Appellee Pfizer Inc.. Service: 08/06/2020 by email. [713174] [20-1871] [Charles Klein] [Entered: 08/06/2020 05:54 PM] (3) |
| Aug 6, 2020 | 26 | Docketing Statement for the Appellee Pfizer Inc.. Service: 08/06/2020 by email. [713175] [20-1871] [Charles Klein] [Entered: 08/06/2020 05:57 PM] (3) |
| Aug 5, 2020 | 21 | Amended Certificate of Interest for Appellant Sanofi-Aventis Deutschland GmbH. Service: 08/05/2020 by email. [712771] [20-1871] [Adam Banks] [Entered: 08/05/2020 03:20 PM] (3) |
| Aug 5, 2020 | 22 | Amended Docketing Statement for the Appellant Sanofi-Aventis Deutschland GmbH. Service: 08/05/2020 by email. [712772] [20-1871] [Adam Banks] [Entered: 08/05/2020 03:22 PM] (4) |
| Aug 5, 2020 | 23 | MOTION of Appellant Sanofi-Aventis Deutschland GmbH to consolidate appeals (2020-1871, 2020-2029, 2020-2032, 2020-2033, 2020-2034), to waive the requirements regarding the brief (Enlarge word limitation, Fed. Cir. R. 32(a)), to set briefing schedule [Consent: opposed]. Service: 08/05/2020 by email. [712826] [20-1871] [Adam Banks] [Entered: 08/05/2020 04:44 PM] (516) |
| Jul 31, 2020 | 18 | ORDER consolidating appeals 20-1871, 20-2029, 20-2032, and 20-2071. The Certified Lists in Appeal Nos. 2020-2029, 20-2032, and 20-2071 are due no later than September 8, 2020. The opening brief is due within 60 days from the filing date of the last-filed of the Certified Lists. Service as of this date by the Clerk of Court. [711620] [20-1871, 20-2029, 20-2032, 20-2071] [EKD] [Entered: 07/31/2020 01:47 PM] (2) |
| Jul 31, 2020 | 19 | Note to File: The following cases are consolidated: 20-1871 Lead with 20-2029, 20-2032, and 20-2071 Consolidated Member Cases. The parties must file all documents in the lead appeal only. [711622] [20-1871, 20-2029, 20-2032, 20-2071] [EKD] [Entered: 07/31/2020 01:56 PM] (0) |
| Jul 31, 2020 | 20 | Note to File: The following cases shall be considered companion cases and assigned to the same merits panel: 20-1871, 20-2033, and 20-2068. [711631] [20-1871, 20-2033, 20-2068] [EKD] [Entered: 07/31/2020 02:19 PM] (0) |
| Jul 20, 2020 | 17 | Certified list received. Service: 07/20/2020 by email. Refer to Fed. Cir. R. 31 for calculating brief deadlines from service of the certified list. [708565] [KMH] [Entered: 07/20/2020 02:15 PM] (120) |
| Jun 24, 2020 | 2 | Entry of appearance for Douglas Carsten as principal counsel for Appellee Mylan Pharmaceuticals Inc.. Service: 06/24/2020 by email. [703334] [20-1871] [Richard Torczon] [Entered: 06/24/2020 12:15 PM] (2) |
| Jun 24, 2020 | 3 | Entry of appearance for Richard Torczon as of counsel for Appellee Mylan Pharmaceuticals Inc.. Service: 06/24/2020 by email. [703339] [20-1871] [Richard Torczon] [Entered: 06/24/2020 12:18 PM] (2) |
| Jun 24, 2020 | 4 | Entry of appearance for Adam Burrowbridge as of counsel for Appellee Mylan Pharmaceuticals Inc.. Service: 06/24/2020 by email. [703340] [20-1871] [Richard Torczon] [Entered: 06/24/2020 12:23 PM] (2) |
| Jun 24, 2020 | 5 | Entry of appearance for Elham F. Steiner as of counsel for Appellee Mylan Pharmaceuticals Inc.. Service: 06/24/2020 by email. [703343] [20-1871] [Richard Torczon] [Entered: 06/24/2020 12:25 PM] (2) |
| Jun 24, 2020 | 6 | Entry of appearance for Wesley Derryberry as of counsel for Appellee Mylan Pharmaceuticals Inc.. Service: 06/24/2020 by email. [703345] [20-1871] [Richard Torczon] [Entered: 06/24/2020 12:27 PM] (2) |
| Jun 24, 2020 | 7 | Entry of appearance for Tasha Thomas as of counsel for Appellee Mylan Pharmaceuticals Inc.. Service: 06/24/2020 by email. [703346] [20-1871] [Richard Torczon] [Entered: 06/24/2020 12:29 PM] (2) |
| Jun 24, 2020 | 8 | Certificate of Interest for Appellee Mylan Pharmaceuticals Inc.. Service: 06/24/2020 by email. [703347] [20-1871] [Richard Torczon] [Entered: 06/24/2020 12:31 PM] (3) |
| Jun 24, 2020 | 9 | Docketing Statement for the Appellee Mylan Pharmaceuticals Inc.. Service: 06/24/2020 by email. [703349] [20-1871] [Richard Torczon] [Entered: 06/24/2020 12:33 PM] (4) |
| Jun 24, 2020 | 10 | Entry of appearance for Adam B. Banks as principal counsel for Appellant Sanofi-Aventis Deutschland GmbH. Service: 06/24/2020 by email. [703408] [20-1871] [Adam Banks] [Entered: 06/24/2020 02:47 PM] (2) |
| Jun 24, 2020 | 11 | Entry of appearance for Elizabeth Stotland Weiswasser as of counsel for Appellant Sanofi-Aventis Deutschland GmbH. Service: 06/24/2020 by email. [703410] [20-1871] [Adam Banks] [Entered: 06/24/2020 02:50 PM] (2) |
| Jun 24, 2020 | 12 | Entry of appearance for Anish R. Desai as of counsel for Appellant Sanofi-Aventis Deutschland GmbH. Service: 06/24/2020 by email. [703413] [20-1871] [Adam Banks] [Entered: 06/24/2020 02:53 PM] (2) |
| Jun 24, 2020 | 13 | Entry of appearance for W. Sutton Ansley as of counsel for Appellant Sanofi-Aventis Deutschland GmbH. Service: 06/24/2020 by email. [703415] [20-1871] [Adam Banks] [Entered: 06/24/2020 02:56 PM] (2) |
| Jun 24, 2020 | 14 | Entry of appearance for Sarah M. Sternlieb as of counsel for Appellant Sanofi-Aventis Deutschland GmbH. Service: 06/24/2020 by email. [703417] [20-1871] [Adam Banks] [Entered: 06/24/2020 02:58 PM] (2) |
| Jun 24, 2020 | 15 | Certificate of Interest for Appellant Sanofi-Aventis Deutschland GmbH. Service: 06/24/2020 by email. [703418] [20-1871] [Adam Banks] [Entered: 06/24/2020 03:01 PM] (3) |
| Jun 24, 2020 | 16 | Docketing Statement for the Appellant Sanofi-Aventis Deutschland GmbH. Service: 06/24/2020 by email. [703419] [20-1871] [Adam Banks] [Entered: 06/24/2020 03:02 PM] (4) |
| Jun 10, 2020 | 1 | Appeal docketed. Received: 05/29/2020. [700267] Entry of Appearance is due 06/24/2020. Certificate of Interest is due on 06/24/2020. Docketing Statement is due 06/24/2020. Certified List is due on 07/20/2020. [LMN] [Entered: 06/10/2020 10:22 AM] (119) |
